Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewStructural Insights into the Assembly of CARMA1 and BCL10Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Essential gene profiles in breast, pancreatic, and ovarian cancer cells.Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.Gain-of-function mutations and immunodeficiency: at a loss for proper tuning of lymphocyte signaling.Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.NF-κB and cancer: a paradigm of Yin-Yang.NF-κB signaling pathways regulated by CARMA family of scaffold proteins.Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis.Regulation of NF-κB by the CARD proteinsLymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activationCooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.A new look at T cell receptor signaling to nuclear factor-κBSynergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.From MALT lymphoma to the CBM signalosome: three decades of discovery.The role of CARMA1 in T cells.Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.Probes to monitor activity of the paracaspase MALT1.A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and DiseaseClinical and Genetic Heterogeneity of Mutations in Psoriatic Skin Disease
P2860
Q27304386-90B4FE70-2E73-4BE9-8770-CA8AF400E58FQ27671461-879720E6-6DDE-45F2-B364-5C1051573D43Q28117437-54A02B50-6E87-4AA3-988A-ABAD70D4BABBQ30375911-F8E2DD58-56A9-4803-A792-32D0014DD01BQ33889168-461061A0-DB06-40CD-9D7C-6E0EC46A53C2Q34268870-7D1359D8-695F-458C-B45A-2B21082F9C41Q34310172-1EAF0258-5C09-48D3-8287-A044153F0508Q34495699-8E5689A4-F37A-48DC-B13B-CF50F96E4E76Q34521887-2AC2EA35-7C8B-4B79-8FB4-870E1B0EF6E8Q35232248-29EB90D9-63FB-4449-80E4-14F711C8306EQ35347919-CC725AD0-1210-4F62-AE6C-929D85A70B16Q35739113-E260B29E-3858-4C29-9D85-B2A59ED5DD72Q35920998-75701DEA-3DA6-4FBA-A034-10E209869FA1Q36435313-97B868F7-248B-4107-8764-D8FCC539B802Q36884567-732E93D3-77A5-477D-8F72-E71E33702387Q36884572-D5C6D64D-033B-4832-AF9C-39BC214389EDQ36906449-AEBAAA0C-DFCE-4F45-A87E-A2184341759DQ37462631-CAF4D184-93E2-474B-92A5-7D191806C761Q37558207-22B96E73-198A-45B8-9AC1-6023FBACBB1DQ37900457-141323EC-3AD0-4AFD-94B3-DDAF46EF0C6BQ38113623-CA1C495A-D806-4CCC-9D3E-A2EDFEB69B1CQ38182355-28D3041D-7CC8-4227-A0E7-33B9B2D6F25BQ38240579-9BCDA56C-E4A7-4F9B-9E6D-19E91E860599Q38264616-0CC93871-7518-40CA-AF7B-28BD1070AFFEQ38831146-18885A1B-4946-4DEC-8708-E9A48E369198Q38923511-104EB9E4-2864-4D1C-9504-7A79ACA947B1Q41883159-4DE47901-DED2-4763-A4FF-E03DE1645DE3Q46356873-C89BC145-A5B2-4B96-B5A9-61C0E940C284Q54976736-7A291FE9-BFC6-4D99-88AC-66C7296286D4Q57072708-AFABE8DE-0C36-4BD2-82EB-005517A986D6Q58553821-3B81EB7D-F498-4062-92E0-EA4BD6D0421E
P2860
Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@ast
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@en
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@nl
type
label
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@ast
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@en
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@nl
prefLabel
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@ast
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@en
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@nl
P2093
P2860
P356
P1433
P1476
Oncogenic CARD11 mutations ind ...... C-responsive inhibitory domain
@en
P2093
Joel L Pomerantz
Rebecca L Lamason
Ryan R McCully
Stefanie M Lew
P2860
P304
P356
10.1021/BI101052D
P407
P577
2010-09-01T00:00:00Z